3Howell A, Buzdar A, Robertson J, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer [J]. Breast Cancer Res Treat, 1999,58(2):157-162.
4Buzdar A, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase Ⅲ trials[J]. Cancer, 1998,83(6): 1142-1152.
5Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate [J]. J Clin Oncol, 1998, 16(2):453-461.
6Gershanovich M,Chaudri H, Campos D, et al. Letrozole, a new oral aromatase inhibitor:randomized trial comparing 2.5mg daily,0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer [J]. Ann Oncol, 1998,9(6): 639-645.
7Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate following tamoxifen failure in advanced breast cancer: results of a phase Ⅲ randomized double-blind trial [J]. J Clin Oncol, 2000, 18(7): 1399-1411.
8Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs anastrozole (Arimidex) : second-line treatment in postmenopausal women with advanced breast cancer [J]. Proc Am Soc Clin Oncol,2002, 21(1): 34a (Abstract 131).
9Nabholtz J, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postm-enopausal women: results of a North American multicenter randomized trial [J]. J Clin Oncol, 2000,18(22): 3758-3767.
10Bonneterre J,Thurlimann B,Robertson J. Anestrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimldex randomized group efficacy and tolerability study[J]. J Clin Oncol,2000,18(22) :3748-3757.
3Ozawa Y, Murakami T, Terada Y, et al. Management of the pain associated with endometriosis: an update of the painful problems[ J]. Tohoku J Exp Med,2006,210(3) :175-188.
4Akira S, Mine K, Kuwabara Y, et al. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy ( draw-back therapy ) for adenomyosis[ J]. Med Sci Monit,2009,15 ( 1 ) : CR1-4.
